search
Back to results

Insomnia Prevalence and Treatment Impact on Systemic Hypertension (Print-HAS)

Primary Purpose

Insomnia, Hypertension

Status
Terminated
Phase
Phase 4
Locations
Brazil
Study Type
Interventional
Intervention
Ramelteon (RozeremR)
sleep hygiene
Sponsored by
University of Sao Paulo
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Insomnia focused on measuring insomnia, hypertension, Ramelteon, sleep hygiene

Eligibility Criteria

30 Years - 75 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion criteria:

  • BMI <40Kg/m2;
  • Availability to participate
  • History of HBP under regular treatment (systolic pressure between 130-160 and diastolic pressure between 80-100 mmHg).

Exclusion criteria:

  • Use of benzodiazepines or "Z" drugs;
  • Night workers;
  • History of severe chronic obstructive pulmonary disease (COPD);
  • Heart failure (ejection fraction <40% on echocardiogram);
  • Prior stroke;
  • Generalized anxiety disorder (GAD-7 >14 points) and severe depression (Beck);
  • Severe liver disease;
  • Alcohol abuse;
  • Advanced chronic kidney disease 4 or 5 (glomerular filtration rate <30ml/min/1.73m2);
  • Patient who is on loop diuretics;
  • Patient with type 1 diabetes;
  • Patient with decompensated type 2 diabetes (Glycated hemoglobin >8%);
  • Urinuria Incontinence;
  • Prostatism;
  • History of active cancer;
  • Pregnancy;
  • Complex sleep behaviors, suicidal behavior;
  • Other formal labeled contraindications, including a history of angioedema with ramelteone and patients using fluvoxamine (a strong inhibitor of CYP1A2)

Sites / Locations

  • Heart Institute (InCor)

Arms of the Study

Arm 1

Arm 2

Arm Type

Other

Other

Arm Label

Control Group

Intervention Group

Arm Description

Sleep hygiene alone (control group)

Sleep Hygiene and Ramelteone (RozeremTM) 8 mg at night

Outcomes

Primary Outcome Measures

Efficacy of insomnia treatment on blood pressure (evaluated by Ambulatory blood pressure monitoring)
To assess the impact of treatment of early insomnia with ramelteon on daytime and nighttime blood presure (in mmHg) in hypertensive patients on 24-hour evaluation of ambulatory blood pressure monitoring.

Secondary Outcome Measures

Efficacy of insomnia treatment on blood pressure (evaluated by office blood pressure)
To evaluate the impact of treating initial insomnia with ramelteone on office blood pressure in hypertensive patients on office blood pressure (in mmHg)
Efficacy of insomnia treatment on Sleep duration
To assess the impact of treating insomnia with ramelteon in hypertensive patients on sleep duration evaluated by actigraphy (and reported in minutes of sleep);
Efficacy of insomnia treatment on sleep quality
To evaluate the impact of treating insomnia with ramelteon in hypertensive patients on sleep quality;
Efficacy of insomnia treatment on subgroups of patients (intending to be a sub-study)
Assess whether the pressure response of insomnia treatment on the primary and secondary outcomes is mediated by the presence of obstructive sleep apnea.

Full Information

First Posted
May 5, 2022
Last Updated
December 27, 2022
Sponsor
University of Sao Paulo
Collaborators
Takeda
search

1. Study Identification

Unique Protocol Identification Number
NCT05414864
Brief Title
Insomnia Prevalence and Treatment Impact on Systemic Hypertension
Acronym
Print-HAS
Official Title
Insomnia Prevalence and Treatment Impact on Systemic Hypertension
Study Type
Interventional

2. Study Status

Record Verification Date
July 2022
Overall Recruitment Status
Terminated
Why Stopped
Takeda suspended financial support. The first phase (observational study) is ongoing.
Study Start Date
May 1, 2022 (Actual)
Primary Completion Date
July 31, 2022 (Actual)
Study Completion Date
September 30, 2022 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Sao Paulo
Collaborators
Takeda

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Insomnia is defined as some difficulty in sleep onset, consolidation, duration, or quality, despite appropriate opportunities for getting sleep. In the last decade, there is growing evidence associating insomnia and high blood pressure, (HBP), coronary disease, heart failure, atrial fibrillation, as well as with an increased mortality rate. Despite the previously mentioned advances, the real impact of insomnia on HBP is unknown. It is unclear whether the diagnosis and pharmacologic treatment of insomnia will have an impact on 24-h BP. The aim of this study is to outline the prevalence of insomnia in patients with HBP followed in the ambulatories from the Hypertension Units at InCor and Hospital das Clínicas. The main hypothesis is that the prevalence of insomnia is high and most patients remain undiagnosed and consequently untreated. For this phase, up to 1,500 patients with HBP will be selected. Besides the medical records with demographic and anthropometric data, personal and familiar background, as well as regular medication, all patients will perform three systematic and standardized blood pressure checks on electric monitors.
Detailed Description
Prevalence of insomnia in patients with HBP The aim of this study is to outline the prevalence of insomnia in patients with HBP followed by the outpatients' clinics at the InCor and Hospital das Clínicas. The main hypothesis is that the prevalence of insomnia is high and most patients remain undiagnosed and consequently untreated. For this phase, up to 1,500 patients with HBP will be recruited. Besides the medical records with demographic and anthropometric data, personal and familiar background, as well as regular medication, all patients will perform three systematic and standardized blood pressure checks on electric monitors. The average of the second and third checks will be the final result. Furthermore, the following exams will be made: Definition of the presence of insomnia following the criteria from DSM V and filling up the insomnia severity index. Evaluation of the Pittsburgh Sleep Quality Index. Evaluation of obstructive sleep apnea by NoSAS score. Evaluation of daytime sleepiness by the Epworth Sleepiness Scale. Filling the DDAS form for evaluation of perception and impact of insomnia on the life of HBP patients. Filling the Beck form for depression evaluation. The clinical characteristics of HBP patients with and without insomnia will be compared testing the hypothesis that patients with insomnia will be under more blood pressure medications and/or uncontrolled bllod pressure than patients without insomnia. If positive, a multivariate analysis will be performed for adjusting for counfonding factors.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Insomnia, Hypertension
Keywords
insomnia, hypertension, Ramelteon, sleep hygiene

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Factorial Assignment
Masking
None (Open Label)
Masking Description
team that evaluate the results of complementary exams
Allocation
Randomized
Enrollment
5 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Control Group
Arm Type
Other
Arm Description
Sleep hygiene alone (control group)
Arm Title
Intervention Group
Arm Type
Other
Arm Description
Sleep Hygiene and Ramelteone (RozeremTM) 8 mg at night
Intervention Type
Drug
Intervention Name(s)
Ramelteon (RozeremR)
Intervention Description
8mg daily
Intervention Type
Behavioral
Intervention Name(s)
sleep hygiene
Intervention Description
sleep behavioral guidelines
Primary Outcome Measure Information:
Title
Efficacy of insomnia treatment on blood pressure (evaluated by Ambulatory blood pressure monitoring)
Description
To assess the impact of treatment of early insomnia with ramelteon on daytime and nighttime blood presure (in mmHg) in hypertensive patients on 24-hour evaluation of ambulatory blood pressure monitoring.
Time Frame
3 months
Secondary Outcome Measure Information:
Title
Efficacy of insomnia treatment on blood pressure (evaluated by office blood pressure)
Description
To evaluate the impact of treating initial insomnia with ramelteone on office blood pressure in hypertensive patients on office blood pressure (in mmHg)
Time Frame
3 months
Title
Efficacy of insomnia treatment on Sleep duration
Description
To assess the impact of treating insomnia with ramelteon in hypertensive patients on sleep duration evaluated by actigraphy (and reported in minutes of sleep);
Time Frame
3 months
Title
Efficacy of insomnia treatment on sleep quality
Description
To evaluate the impact of treating insomnia with ramelteon in hypertensive patients on sleep quality;
Time Frame
3 months
Title
Efficacy of insomnia treatment on subgroups of patients (intending to be a sub-study)
Description
Assess whether the pressure response of insomnia treatment on the primary and secondary outcomes is mediated by the presence of obstructive sleep apnea.
Time Frame
3 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
30 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion criteria: BMI <40Kg/m2; Availability to participate History of HBP under regular treatment (systolic pressure between 130-160 and diastolic pressure between 80-100 mmHg). Exclusion criteria: Use of benzodiazepines or "Z" drugs; Night workers; History of severe chronic obstructive pulmonary disease (COPD); Heart failure (ejection fraction <40% on echocardiogram); Prior stroke; Generalized anxiety disorder (GAD-7 >14 points) and severe depression (Beck); Severe liver disease; Alcohol abuse; Advanced chronic kidney disease 4 or 5 (glomerular filtration rate <30ml/min/1.73m2); Patient who is on loop diuretics; Patient with type 1 diabetes; Patient with decompensated type 2 diabetes (Glycated hemoglobin >8%); Urinuria Incontinence; Prostatism; History of active cancer; Pregnancy; Complex sleep behaviors, suicidal behavior; Other formal labeled contraindications, including a history of angioedema with ramelteone and patients using fluvoxamine (a strong inhibitor of CYP1A2)
Facility Information:
Facility Name
Heart Institute (InCor)
City
São Paulo
State/Province
Sao Paulo
ZIP/Postal Code
05403-900
Country
Brazil

12. IPD Sharing Statement

Citations:
PubMed Identifier
18853708
Citation
Schutte-Rodin S, Broch L, Buysse D, Dorsey C, Sateia M. Clinical guideline for the evaluation and management of chronic insomnia in adults. J Clin Sleep Med. 2008 Oct 15;4(5):487-504.
Results Reference
background
PubMed Identifier
25747141
Citation
Ford ES, Cunningham TJ, Giles WH, Croft JB. Trends in insomnia and excessive daytime sleepiness among U.S. adults from 2002 to 2012. Sleep Med. 2015 Mar;16(3):372-8. doi: 10.1016/j.sleep.2014.12.008. Epub 2015 Jan 14.
Results Reference
background
PubMed Identifier
21195389
Citation
Roth T, Coulouvrat C, Hajak G, Lakoma MD, Sampson NA, Shahly V, Shillington AC, Stephenson JJ, Walsh JK, Kessler RC. Prevalence and perceived health associated with insomnia based on DSM-IV-TR; International Statistical Classification of Diseases and Related Health Problems, Tenth Revision; and Research Diagnostic Criteria/International Classification of Sleep Disorders, Second Edition criteria: results from the America Insomnia Survey. Biol Psychiatry. 2011 Mar 15;69(6):592-600. doi: 10.1016/j.biopsych.2010.10.023. Epub 2010 Dec 31.
Results Reference
background
PubMed Identifier
16983058
Citation
Pearson NJ, Johnson LL, Nahin RL. Insomnia, trouble sleeping, and complementary and alternative medicine: Analysis of the 2002 national health interview survey data. Arch Intern Med. 2006 Sep 18;166(16):1775-82. doi: 10.1001/archinte.166.16.1775.
Results Reference
background
PubMed Identifier
23720241
Citation
Castro LS, Poyares D, Leger D, Bittencourt L, Tufik S. Objective prevalence of insomnia in the Sao Paulo, Brazil epidemiologic sleep study. Ann Neurol. 2013 Oct;74(4):537-46. doi: 10.1002/ana.23945. Epub 2013 Sep 16.
Results Reference
background
PubMed Identifier
28153671
Citation
Javaheri S, Redline S. Insomnia and Risk of Cardiovascular Disease. Chest. 2017 Aug;152(2):435-444. doi: 10.1016/j.chest.2017.01.026. Epub 2017 Jan 30.
Results Reference
background
PubMed Identifier
22892811
Citation
Fernandez-Mendoza J, Vgontzas AN, Liao D, Shaffer ML, Vela-Bueno A, Basta M, Bixler EO. Insomnia with objective short sleep duration and incident hypertension: the Penn State Cohort. Hypertension. 2012 Oct;60(4):929-35. doi: 10.1161/HYPERTENSIONAHA.112.193268. Epub 2012 Aug 14.
Results Reference
background
PubMed Identifier
19413143
Citation
Vgontzas AN, Liao D, Bixler EO, Chrousos GP, Vela-Bueno A. Insomnia with objective short sleep duration is associated with a high risk for hypertension. Sleep. 2009 Apr;32(4):491-7. doi: 10.1093/sleep/32.4.491.
Results Reference
background
PubMed Identifier
14676413
Citation
Suka M, Yoshida K, Sugimori H. Persistent insomnia is a predictor of hypertension in Japanese male workers. J Occup Health. 2003 Nov;45(6):344-50. doi: 10.1539/joh.45.344.
Results Reference
background
PubMed Identifier
22025601
Citation
Laugsand LE, Vatten LJ, Platou C, Janszky I. Insomnia and the risk of acute myocardial infarction: a population study. Circulation. 2011 Nov 8;124(19):2073-81. doi: 10.1161/CIRCULATIONAHA.111.025858. Epub 2011 Oct 24.
Results Reference
background
PubMed Identifier
11886479
Citation
Mallon L, Broman JE, Hetta J. Sleep complaints predict coronary artery disease mortality in males: a 12-year follow-up study of a middle-aged Swedish population. J Intern Med. 2002 Mar;251(3):207-16. doi: 10.1046/j.1365-2796.2002.00941.x.
Results Reference
background
PubMed Identifier
23462728
Citation
Laugsand LE, Strand LB, Platou C, Vatten LJ, Janszky I. Insomnia and the risk of incident heart failure: a population study. Eur Heart J. 2014 Jun 1;35(21):1382-93. doi: 10.1093/eurheartj/eht019. Epub 2013 Mar 5.
Results Reference
background
PubMed Identifier
28561943
Citation
Han X, Yang Y, Chen Y, Gao L, Yin X, Li H, Qiu J, Wang Y, Zhou Y, Xia Y. Association between insomnia and atrial fibrillation in a Chinese population: A cross-sectional study. Clin Cardiol. 2017 Sep;40(9):765-769. doi: 10.1002/clc.22731. Epub 2017 May 31.
Results Reference
background
PubMed Identifier
24226807
Citation
Li Y, Zhang X, Winkelman JW, Redline S, Hu FB, Stampfer M, Ma J, Gao X. Association between insomnia symptoms and mortality: a prospective study of U.S. men. Circulation. 2014 Feb 18;129(7):737-46. doi: 10.1161/CIRCULATIONAHA.113.004500. Epub 2013 Nov 13.
Results Reference
background
PubMed Identifier
28391289
Citation
McGrath ER, Espie CA, Power A, Murphy AW, Newell J, Kelly C, Duffy N, Gunning P, Gibson I, Bostock S, O'Donnell MJ. Sleep to Lower Elevated Blood Pressure: A Randomized Controlled Trial (SLEPT). Am J Hypertens. 2017 Mar 1;30(3):319-327. doi: 10.1093/ajh/hpw132.
Results Reference
background
PubMed Identifier
2748771
Citation
Buysse DJ, Reynolds CF 3rd, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res. 1989 May;28(2):193-213. doi: 10.1016/0165-1781(89)90047-4.
Results Reference
background
PubMed Identifier
27321086
Citation
Marti-Soler H, Hirotsu C, Marques-Vidal P, Vollenweider P, Waeber G, Preisig M, Tafti M, Tufik SB, Bittencourt L, Tufik S, Haba-Rubio J, Heinzer R. The NoSAS score for screening of sleep-disordered breathing: a derivation and validation study. Lancet Respir Med. 2016 Sep;4(9):742-748. doi: 10.1016/S2213-2600(16)30075-3. Epub 2016 Jun 16.
Results Reference
background
PubMed Identifier
1798888
Citation
Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep. 1991 Dec;14(6):540-5. doi: 10.1093/sleep/14.6.540.
Results Reference
background
PubMed Identifier
23066376
Citation
Berry RB, Budhiraja R, Gottlieb DJ, Gozal D, Iber C, Kapur VK, Marcus CL, Mehra R, Parthasarathy S, Quan SF, Redline S, Strohl KP, Davidson Ward SL, Tangredi MM; American Academy of Sleep Medicine. Rules for scoring respiratory events in sleep: update of the 2007 AASM Manual for the Scoring of Sleep and Associated Events. Deliberations of the Sleep Apnea Definitions Task Force of the American Academy of Sleep Medicine. J Clin Sleep Med. 2012 Oct 15;8(5):597-619. doi: 10.5664/jcsm.2172.
Results Reference
background
PubMed Identifier
27128710
Citation
Chowdhuri S, Quan SF, Almeida F, Ayappa I, Batool-Anwar S, Budhiraja R, Cruse PE, Drager LF, Griss B, Marshall N, Patel SR, Patil S, Knight SL, Rowley JA, Slyman A; ATS Ad Hoc Committee on Mild Obstructive Sleep Apnea. An Official American Thoracic Society Research Statement: Impact of Mild Obstructive Sleep Apnea in Adults. Am J Respir Crit Care Med. 2016 May 1;193(9):e37-54. doi: 10.1164/rccm.201602-0361ST.
Results Reference
background
PubMed Identifier
15683149
Citation
Edinger JD, Bonnet MH, Bootzin RR, Doghramji K, Dorsey CM, Espie CA, Jamieson AO, McCall WV, Morin CM, Stepanski EJ; American Academy of Sleep Medicine Work Group. Derivation of research diagnostic criteria for insomnia: report of an American Academy of Sleep Medicine Work Group. Sleep. 2004 Dec 15;27(8):1567-96. doi: 10.1093/sleep/27.8.1567.
Results Reference
result

Learn more about this trial

Insomnia Prevalence and Treatment Impact on Systemic Hypertension

We'll reach out to this number within 24 hrs